Sadia Dar, MD
Family Medicine · Smyrna, TNNPI 1326115577
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 111 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 15.2% — the pattern of someone who eats at a lot of different presentations.
Across 111 payments — averaging $17.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$302
- Amgen$172
- Novo Nordisk$167
- AbbVie$156
- GSK$139
- Lilly USA, LLC$122
- plus $928 from 25 others
Across 22 payments — averaging $2199.58 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$19K
- Shionogi Inc$12K
- Swedish Orphan Biovitrum AB$8K
- Kowa Research Institute, Inc.$4K
- Pfizer$2K
- Paratek Pharmaceuticals, Inc.$1K
- plus $3K from 3 others
What the payments were for
- Food & beverage$1,986100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 18 | $302 |
| Amgen | 10 | $172 |
| Novo Nordisk | 10 | $167 |
| AbbVie | 8 | $156 |
| GSK | 7 | $139 |
| Lilly USA, LLC | 7 | $122 |
| Abbott | 5 | $102 |
| Exact Sciences | 5 | $93 |
| AstraZeneca | 5 | $81 |
| Indivior Inc. | 4 | $78 |
| Dexcom, Inc. | 4 | $76 |
| Merck | 5 | $76 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $48 |
| Astellas Pharma US Inc | 2 | $44 |
| Boston Scientific | 1 | $38 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $37 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $34 |
| Boehringer Ingelheim | 1 | $27 |
| Redhill Biopharma Inc. | 1 | $18 |
| Esperion Therapeutics, Inc. | 1 | $18 |
| Phadia US Inc. | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $17 |
| Tris Pharma Inc | 1 | $17 |
| Axonics, Inc. | 1 | $16 |
| Hologic Sales And Service, LLC | 1 | $15 |
| Cardiovascular Systems Inc. | 1 | $15 |
| Genentech USA, Inc. | 1 | $15 |
| Currax Pharmaceuticals LLC | 1 | $15 |
| Bristol Myers Squibb | 1 | $13 |
| Orexo US, Inc. | 1 | $13 |
| Bardy Diagnostics, Inc. | 1 | $5 |
How this compares
$1,986 in reported general payments places this provider in the 70th percentile of 2,087 family medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 64 | $87,415 |
| MounjaroTirzepatide | 44 | $45,392 |
| JanuviaSitagliptin Phosphate | 20 | $30,490 |
| JardianceEmpagliflozin | 22 | $26,862 |
| XareltoRivaroxaban | 23 | $23,288 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 98 | $14,149 |
| Tresiba Flextouch U-100Insulin Degludec | 16 | $10,339 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 20 | $4,403 |
| PremarinEstrogens, Conjugated | 11 | $3,883 |
| LantusInsulin Glargine,hum.Rec.Anlog | 13 | $3,242 |
| Omeprazole | 152 | $2,660 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 55 | $2,607 |
| Ezetimibe | 30 | $1,806 |
| Rosuvastatin Calcium | 141 | $1,606 |
| Atorvastatin Calcium | 144 | $1,516 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $167 | $87,41564 claims |
| Lilly USA, LLCMounjaro | $122 | $45,39244 claims |
| MerckJanuvia | $76 | $30,49020 claims |
| Boehringer IngelheimJardiance | $27 | $26,86222 claims |
| GSKShingrix | $139 | $4,40320 claims |
| PfizerPremarin | $302 | $3,88311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,087 family medicine providers in Tennessee.
Other family medicine in Smyrna
- Joshua HixsonSmyrna$18K
- Kirsten BunceSmyrna$14K
- Kevin DennisFranklin$354K
- Charolette JacksonBartlett$162K
- Keren HolmesNashville$58K
- Kabir Harricharan SinghNewport$49K
- Khaisha GistAntioch$49K
- Jerry PunchKnoxville$45K
- Christopher HollowayAntioch$41K
- Curtis JantziKingsport$39K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.